|A healthcare worker holds a vial of the Moderna COVID-19 vaccine at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in Manhattan in New York City, New York, US, January 29, 2021. (Photo: REUTERS)
Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults.
It cited interim data that has yet to be peer reviewed. The Moderna COVID-19 vaccine is authorized for adults over the age of 18 years and is waiting for a response to its June application for children aged 12 through 17.
It is behind rivals Pfizer and BioNTech, whose vaccine has been authorized for ages 12 and up since May. A panel of outside advisers to the US Food and Drug Administration will meet on Tuesday to decide whether to recommend Pfizer's vaccine in children aged five to 11 years.